When to Resume Eliquis After TAVR
Apixaban (Eliquis) should be restarted 48-72 hours after TAVR once adequate hemostasis is established, treating TAVR as a high bleeding risk procedure. 1
Risk Stratification: TAVR as a High Bleeding Risk Procedure
TAVR must be classified as a high bleeding risk procedure due to:
- Vascular access complications (femoral artery puncture)
- Risk of cardiac perforation
- Potential for significant hemorrhage requiring transfusion
- Need for secure hemostasis at multiple sites
This classification drives the timing of anticoagulation resumption.
Timing Algorithm for Apixaban Resumption
Standard Approach (Most Patients)
- Wait 48-72 hours post-procedure before restarting apixaban 1
- Confirm adequate hemostasis at vascular access site
- Ensure no active bleeding or hemodynamic instability
- Resume at full therapeutic dose (5 mg twice daily, or 2.5 mg twice daily if dose-reduction criteria apply) 2
High Thromboembolic Risk Patients
For patients with very high stroke risk (e.g., recent stroke, CHADS₂-VASc ≥5, mechanical valve contraindication):
- Consider reduced-dose apixaban (2.5 mg twice daily) starting at 48 hours 3
- Increase to full dose at 72 hours if hemostasis remains secure
- This mirrors the approach used for high-risk thromboembolism patients after major surgery
Critical Considerations
Hemostasis Assessment
Before restarting apixaban, verify:
- Vascular access site: No hematoma expansion, stable hemoglobin
- Cardiac status: No pericardial effusion on echocardiography
- Hemodynamic stability: No ongoing transfusion requirements
- Surgical team clearance: Explicit confirmation that hemostasis is adequate
Avoid Premature Resumption
Do not restart apixaban within 24 hours of TAVR 1. The rapid onset of action (peak effect in 1-3 hours) 3 means premature resumption carries similar bleeding risk to therapeutic-dose LMWH bridging, which is inappropriate immediately post-procedure.
No Bridging Therapy Required
Bridging anticoagulation is NOT recommended during the 48-72 hour interruption period 2. The short interruption window and rapid onset of apixaban make bridging unnecessary and potentially harmful.
Special Populations
Renal Impairment
- Standard 48-72 hour timing applies regardless of renal function
- Apixaban has only 25% renal clearance 3, making it more predictable than dabigatran in this setting
- Ensure dose-reduction criteria are applied if CrCl 15-29 mL/min (2.5 mg twice daily) 2
Patients Already on Anticoagulation for Atrial Fibrillation
Recent evidence suggests continuation of anticoagulation through TAVR may be safe 4, with no increase in bleeding and potentially less need for transfusion. However, this approach requires:
- Experienced TAVR center
- Careful patient selection
- Explicit discussion with the procedural team
If anticoagulation was held pre-procedure, follow the standard 48-72 hour resumption protocol.
Common Pitfalls to Avoid
Resuming too early: The 24-hour window is for LOW bleeding risk procedures only (e.g., dental work, minor dermatologic procedures) 3
Using bridging therapy: This adds bleeding risk without benefit for the short interruption period 2
Forgetting dose adjustments: Verify if patient meets criteria for 2.5 mg twice daily dosing (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL) 2
Ignoring vascular complications: Any access site hematoma or retroperitoneal bleeding should delay resumption beyond 72 hours
Inadequate communication: Ensure explicit handoff between procedural team and inpatient team regarding timing of anticoagulation resumption
Documentation Requirements
When restarting apixaban post-TAVR, document:
- Time of last dose pre-procedure
- Confirmation of hemostasis (access site check, stable hemoglobin, no effusion)
- Exact time of first post-procedure dose
- Rationale if deviating from 48-72 hour window
- Patient education on bleeding precautions